VirginiaHB10762026 Regular SessionHouseWALLET

Pharmaceutical Substance Manufacturing Grant Fund; created.

Sponsored By: Amy J. Laufer (Democratic)

Became Law

Summary

Pharmaceutical Substance Manufacturing Grant Fund. Establishes the Pharmaceutical Substance Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $34 million per fiscal year and in an aggregate amount not to exceed $191,255,000, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $4 billion and create and maintain at least 500 new full-time jobs. This bill is identical to SB 527.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

3 provisions identified: 0 benefits, 0 costs, 3 mixed.

State grants for pharma manufacturing with caps

The law creates the Pharmaceutical Substance Manufacturing Grant Fund in the state treasury. The fund keeps its balance and interest and does not revert to the general fund. Total grants are capped at $191,255,000, with no more than $34,000,000 paid in any one fiscal year. Grants may be paid in up to 20 annual installments; any amounts not earned by then are forfeited. Grants start no earlier than the fiscal year beginning July 1, 2026 and run through the fiscal year beginning July 1, 2045, unless extended by the performance agreement. Every payment is subject to a specific yearly appropriation by the General Assembly, and recipients may use the money for construction, development, or any other lawful purpose.

Who qualifies for these pharma grants

A company qualifies only if it makes pharmaceutical substances and, on or after July 1, 2025 and before July 1, 2045, plans at least $4 billion in capital investment and 500 new full‑time jobs. The facility must be at or near the company’s operations in Albemarle County. The company must sign a performance agreement with the Commonwealth and VEDP that sets the targets. A “new full‑time job” pays at least $160,750 a year (with standard fringe benefits) and is at least 35 hours a week for 48 weeks, or 1,680 hours a year. Seasonal, temporary, contractor, vendor, and similar jobs do not count.

Yearly filings and payments for pharma grants

To receive each yearly installment, the company must file proof of jobs and capital investment with the Secretary by October 1, showing results through the end of the prior fiscal year. Missing the deadline defers the payment. After a complete filing, the Secretary certifies the grant amount within 60 days. The state issues the check in the next fiscal year, and only if the General Assembly has specifically appropriated the money. The company must allow inspection of relevant records; properly marked documents are treated as confidential and proprietary.

Sponsors & Cosponsors

Sponsor

  • Amy J. Laufer

    Democratic • House

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

All Roll Calls

Yes: 208 • No: 5

Senate vote 2/19/2026

Passed Senate Block Vote

Yes: 39 • No: 0

Senate vote 2/18/2026

Constitutional reading dispensed Block Vote (on 2nd reading)

Yes: 38 • No: 0

Senate vote 2/17/2026

Reported from Finance and Appropriations

Yes: 13 • No: 0

House vote 2/5/2026

Read third time and passed House

Yes: 92 • No: 5

House vote 1/30/2026

Reported from Appropriations

Yes: 21 • No: 0

House vote 1/28/2026

Subcommittee recommends reporting

Yes: 5 • No: 0 • Other: 1

Actions Timeline

  1. Acts of Assembly Chapter text (CHAP0808)

    4/13/2026Governor
  2. Approved by Governor-Chapter 808 (effective 7/1/2026)

    4/13/2026Governor
  3. Governor's Action Deadline 11:59 p.m., April 13, 2026

    3/10/2026Governor
  4. Enrolled Bill communicated to Governor on March 10, 2026

    3/10/2026House
  5. Fiscal Impact Statement from Department of Planning and Budget (HB1076)

    2/23/2026House
  6. Bill text as passed House and Senate (HB1076ER)

    2/23/2026House
  7. Enrolled

    2/23/2026House
  8. Signed by President

    2/23/2026Senate
  9. Signed by Speaker

    2/23/2026House
  10. Passed Senate Block Vote (39-Y 0-N 0-A)

    2/19/2026Senate
  11. Read third time

    2/19/2026Senate
  12. Constitutional reading dispensed Block Vote (on 2nd reading) (38-Y 0-N 0-A)

    2/18/2026Senate
  13. Rules suspended

    2/18/2026Senate
  14. Passed by for the day

    2/18/2026Senate
  15. Read second time

    2/18/2026Senate
  16. Reported from Finance and Appropriations (13-Y 0-N)

    2/17/2026Senate
  17. Referred to Committee on Finance and Appropriations

    2/6/2026Senate
  18. Constitutional reading dispensed (on 1st reading)

    2/6/2026Senate
  19. Read third time and passed House (92-Y 5-N 0-A)

    2/5/2026House
  20. Read second time and engrossed

    2/4/2026House
  21. Moved from Uncontested Calendar to Regular Calendar

    2/4/2026House
  22. Read first time

    2/3/2026House
  23. Reported from Appropriations (21-Y 0-N)

    1/30/2026House
  24. Subcommittee recommends reporting (5-Y 0-N)

    1/28/2026House
  25. Fiscal Impact Statement from Department of Planning and Budget (HB1076)

    1/23/2026House

Bill Text

Related Bills

Back to State Legislation